Digestive and Liver Disease Supplements This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Current challenges and future trends in liver transplantation
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Manuel L. Rodríguez-Perálvarez, Jose Luis Montero, Manuel De la Mata GarcíaAbstractIn Liver Transplantation (LT) units the clinicians routinely deal with complex decision making situations that cannot always be solved with the available scientific evidence. They include selection of the best candidates for LT, minimizing mortality and drop-out rates within the waiting list (WL) and rationalizing donor–recipient matching. These topics constitute some of the current challenges in LT and they may drive a number of ...
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Liver transplantation: is it a sustainable practice?
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Franco FilipponiAbstractDespite its widespread diffusion, liver transplantation (LT) still remains one of the most resource consuming surgical procedures. In times of economic constraints, the entire medical community is discussing the strategies necessary to allow a sustainable development of LT. Sustainability is the capacity to endure and, in ecology, the word describes how biological systems remain diverse and productive over time. In clinical practice, sustainability is the potential for long-term maintenance of...
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Management of hepatitis B virus infection in the pre-transplant setting
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Martín Prieto, María García-ElizAbstractLiver transplantation remains the ultimate cure for patients with hepatitis B virus-related end-stage liver disease. Clinical Practice Guidelines currently recommend that patients with decompensated HBV cirrhosis should be treated without delay with nucleos(t)ide analogues regardless of the patient's serum ALT, HBV DNA level, and HBeAg status. The main goal of pre-transplantation antiviral therapy is to achieve a rapid and prolonged suppression of viral replication and thus ...
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Optimization of hepatitis B virus prophylaxis after liver transplantation
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Paolo De SimoneAbstractA combination of hepatitis B immunoglobulins (HBIg) and nucleos(t)ide analogues (NA) is currently recommended for HBV prophylaxis after liver transplantation (LT), but the optimal regimen is still controversial. Several issues concerning use of HBIg after LT still await definitive clarification, such as dosage (high vs. low); timing (ab initio vs. delayed); schedule (on demand vs. fixed-dose); route of administration (intravenous vs. intramuscular vs. subcutaneous), and duration (short-term vs....
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Management of HBV resistance in the post-transplant setting
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Alfredo MarzanoAbstractIn western countries, about 10–25% of patients undergoing liver transplantation (LT) are HBsAg carriers. In Asia, HBV-related liver disease is the leading indication to LT. After surgery hepatitis B can develop in patients transplanted for HBV-related disease or in HBsAg-negative recipients of anti-HBc positive grafts. In the last years prophylaxis with HBIG and/or antivirals has been proposed in both conditions with excellent results. However, lack of efficacy of prophylaxis is frequently as...
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Non-invasive diagnosis of liver fibrosis in the transplant setting
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Gonzalo Crespo, Zoe MariñoAbstractRecurrent hepatitis C after liver transplantation is a rapidly evolving condition in which fibrosis deposition is accelerated, with 30% of patients developing graft cirrhosis within the first 5 years after transplantation. Antiviral therapy after transplantation achieves sustained virological response (SVR) in approximately 30% of patients, and a milder fibrosis stage at treatment seems to increase the probabilities of response to treatment. Importantly, SVR to antiviral therapy in ...
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Treatment of hepatitis C in the post-transplant setting
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Marina BerenguerAbstractCirrhosis with/without hepatocellular carcinoma is the primary indication for liver transplantation (LT) in many countries. Hepatitis C virus (HCV) reinfection occurs universally resulting in HCV-graft disease with progression to cirrhosis in about one third of cases after 5 years. Graft failure secondary to recurrent HCV is now the most frequent cause of death, graft failure and need for retransplantation in these patients, with a cumulative risk of allograft failure due to recurrent disease ...
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Facing HCV recurrence after liver transplantation: antiviral therapy response and clinical outcome
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Maria Rendina, Stefano Fagiuoli, Patrizia Burra, Nicola Maurizio Castellaneta, Marianna Zappimbulso, Antonio Castellaneta, Roberto Bringiotti, Salvatore Fiabio Rizzi, Annamaria Squicciarino, Luigi Lupo, Alfredo Di LeoAbstractEnd-stage liver disease related to HCV infection is the most common indication for liver transplantation both in Europe and in USA (http://www.UNOS.org; http://www.ELTR.org). The results of liver transplantation for this indication are negatively affected by the high rate of viral recurrence whic...
Source: Digestive and Liver Disease Supplements - July 10, 2018 Category: Gastroenterology Source Type: research

Editorial Board
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Maria Laura Annunziata, Fabrizio Bossa, Rosamaria Bozzi, Flavio Caprioli, Andrea Cassinotti, Giuseppe Costantino, Gionata Fiorino, Sara Onali, Mariabeatrice Principi, Sara Renna, Rosy Tambasco (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Spondyloarthropathy associated with Crohn's disease treated with adalimumab
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Maria Laura Annunziata, Michele Cicala (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Long-term remission with adalimumab in steroid-dependent Crohn's disease patients with multiple drug intolerances
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Fabrizio Bossa, Giuseppe Biscaglia, Antonio Merla, Fulvia Terracciano (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Adalimumab and endoscopic dilatation in the treatment of inflammatory strictures due to Crohn's disease: A case report of a treatment-naïve patient
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Rosamaria Bozzi, Pietro Schettino, Angelo Pezzullo, Domenico Cattaneo (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Adalimumab is safe and effective in re-inducing clinical remission after post-surgical relapse of Crohn's disease: A case report
We present the case of a 36-year-old patient with ileo-colonic stricturing Crohn's disease that recurred after surgery, did not respond to maximal medical therapy and was only partially responsive to treatment with adalimumab administered subcutaneously. The patient underwent surgery following an episode of intestinal obstruction, revealing chronic, adhesive peritonitis, with the intestinal loops fixed strongly together, and a fibrotic stricture of the pre-anastomotic ileum. The numerous adhesions were carefully separated and the stenotic tract of ileum was resected. Following the resection the patient had an early clinica...
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research

Is mucosal healing a predictor of decreased risk of Crohn's disease relapse after withdrawal of 1-year, successful adalimumab?
Publication date: December 2010Source: Digestive and Liver Disease Supplements, Volume 4, Issue 1Author(s): Andrea Cassinotti, Maria Fichera, Sandro Ardizzone, Gabriele Bianchi Porro (Source: Digestive and Liver Disease Supplements)
Source: Digestive and Liver Disease Supplements - July 5, 2018 Category: Gastroenterology Source Type: research